A Phase 2 interventional study of Pumitamig and Carboplatin in Early-Stage Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Not yet recruiting at 50 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer
6,641 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,665 are open to participants now.
This study's planned enrollment of 80 is above the median of 62 across 5,327 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 118 are open to participants now.
Of its 435 completed or terminated interventional studies of FDA-regulated products, 227 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Drug: Pumitamig · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Pemetrexed
Drug: Pumitamig · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Pemetrexed
Specified dose on specified days
Also known as: BMS-986545, BNT327
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Achievement of pathologic complete response (pCR) by blinded independent pathology review (BIPR)
Time frame: Up to 6 weeks after last dose
Incidence of all-causality
Time frame: Up to 5 years from safety follow-up
Number of participants with treatment-related adverse events (TRAEs)
Time frame: Up to 90 days after surgery
Number of participants with serious adverse events (SAEs)
Time frame: Up to 90 days after surgery
Number of participants with immune related adverse events (irAEs)
Time frame: Up to 90 days after surgery
Number of participants with bleeding events
Time frame: Up to 90 days after surgery
Number of participants with adverse events (AEs) leading to dose delay
Time frame: Up to 90 days after surgery
Number of participants with AEs leading to dose discontinuation
Time frame: Up to 90 days after surgery
Number of deaths
Time frame: Up to 5 years
Number of participants with laboratory abnormalities
Time frame: Up to 30 days before surgery
Number of participants with surgery completion within 6 weeks after neoadjuvant therapy, without treatment-related cancellation, with documentation of resection status
Time frame: Up to 6 weeks after last dose
Number of participants with delayed or cancelled surgery
Time frame: Up to 6 weeks after last dose
Number of participants with AEs associated with surgery complications
Time frame: Up to 90 days after surgery
Number of participants with SAEs associated with surgery complications
Time frame: Up to 90 days after surgery
Achievement of major pathologic response (MPR) (by blinded independent pathology review (BIPR))
Time frame: Up to 6 weeks after last dose
Event-free survival (EFS) (by investigator)
Time frame: Up to 5 years
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Start is estimated for Nov 2026; primary completion for Mar 2028, 15 months later.
Of 292 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 15 months is below that.
Counting every sponsor, half of 970 studies reached it within 48 months; a quarter within 30 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pumitamig
Carcinoma, Non-Small-Cell Lung →